ModifiedBlue Cross Blue Shield - MassachusettsPolicy 122

Chelation Therapy — Medical Necessity and Investigational Uses

This policy governs medical necessity and investigational determinations for chelation therapy for Blue Cross Blue Shield - Massachusetts commercial members (HMO, POS, PPO, Indemnity). It specifies covered indications, investigational uses, coding guidance, and authorization rules for inpatient and outpatient settings.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyChelation Therapy — Medical Necessity and Investigational Uses

Policy CodePolicy 122

Change TypeClinical updateinvestigational list expanded

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for inpatient chelation therapy; outpatient prior authorization is not required for Commercial HMO/POS, PPO, and Indemnity.

SourceLink

POLICY UPDATE CHANGES

Policy statement changed to include Parkinson disease among the listed investigational indications.

Outcomes from the TACT2 randomized trial (restricted to individuals with diabetes) published in 2024 failed to replicate the findings from the original TACT trial.

Summary of evidence states that overall evidence is insufficient to determine that chelation therapy results in an improvement in net health outcome for listed conditions.

Medicare information removed from this policy; reference to Medicare handled in MP #132.

4explicit medically necessary indications listed

>=7off-label/investigational indications enumerated

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Chelation Therapy

Medically Necessary Indications

Chelation therapy is MEDICALLY NECESSARY for the following:

Medically necessary indications: Extreme conditions of metal toxicity; Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or due to nontransfusion-dependent thalassemia (NTDT); Wilson's disease (hepatolenticular degeneration); Lead poisoning.

From policy statements

Medically necessary when other modalities have failed: Control of ventricular arrhythmias or heart block associated with digitalis toxicity; Emergency treatment of hypercalcemia.

These indications require failure of other modalities per policy

Investigational / Off-Label Indications

Chelation therapy is considered INVESTIGATIONAL for the following off-label indications:

Investigational indications: Alzheimer disease; Arthritis (includes rheumatoid arthritis); Atherosclerosis (e.g., coronary artery disease, secondary prevention post–myocardial infarction, or peripheral vascular disease); Autism; Diabetes; Multiple sclerosis; Parkinson disease.

Policy lists these as investigational; evidence insufficient to determine improvement in net health outcome

Not Medically Necessary

Not Medically Necessary Agent: NaEDTA (disodium EDTA) as chelation therapy is considered NOT MEDICALLY NECESSARY.

Policy explicitly names NaEDTA as not medically necessary

General coverage conclusion

Summary of evidence and coverage implication

Overall evidence: The evidence is insufficient to determine that chelation therapy results in an improvement in the net health outcome for the listed conditions.

Includes randomized trials and case series; TACT suggested benefit in prior MI patients (greater in diabetics) but had limitations; TACT2 (diabetes-only, 2024) failed to replicate TACT.

HCPCS M0300 (IV chelation therapy (chemical endarterectomy)) is designated as investigational for Commercial Members (Managed Care [HMO and POS], PPO, and Indemnity) and is not covered for routine use under this policy.

Overall, the policy concludes that the evidence is insufficient to support routine coverage of chelation therapy for cardiovascular or other off-label indications. The original Trial to Assess Chelation Therapy (TACT) reported a reduction in cardiovascular events among patients with prior myocardial infarction, with a larger apparent benefit in those with diabetes, but the trial had important limitations (for example, high dropout rates). The follow-up randomized trial, TACT2, which enrolled only individuals with diabetes, published in 2024, failed to replicate TACT’s findings. Given these results and the limited RCT and case series data across other indications, chelation therapy is not supported for routine coverage for the listed off-label uses.

The policy explicitly states that NaEDTA (disodium EDTA) as chelation therapy is NOT MEDICALLY NECESSARY.

Chelation therapy is considered investigational for multiple off-label conditions, including Alzheimer disease, cardiovascular disease (eg, atherosclerosis, secondary prevention post-MI), autism spectrum disorder, diabetes, multiple sclerosis, Parkinson disease, and arthritis (including rheumatoid arthritis). The evidence base (RCTs and case series) does not demonstrate improvement in net health outcome for these indications.

Coding Guidance and Relevant Codes

ICD-10 Diagnosis Codes Considered Medically Necessary when submitted with HCPCSICD-10

D56.0	Alpha thalassemia
D56.1	Beta thalassemia
D56.5	Hemoglobin E-beta thalassemia
E83.00	Disorder of copper metabolism, unspecified
E83.01	Wilson's disease
E83.09	Other disorders of copper metabolism
E83.111	Hemochromatosis due to repeated red blood cell transfusions
E83.52	Hypercalcemia
I44.0	Atrioventricular block, first degree
I44.1	Atrioventricular block, second degree

1–10 of 28

1/3

Covered HCPCS Codes (informational list)HCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, [Desferal] 500 mg.
J3520	Edetate disodium, per 150 mg.
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Investigational HCPCS CodeHCPCSNot Covered

M0300

IV chelation therapy (chemical endarterectomy)

Code–criteria linkage

Coverage linkageThe listed HCPCS procedure codes (J0470, J0600, J0895, J3520, S9355) are covered only when submitted with one of the listed ICD-10 diagnoses and when the policy's medical necessity criteria for chelation therapy are met.

Required diagnosis submissionProviders must submit an appropriate ICD-10 diagnosis from the policy's medically necessary list (eg, D56.0, E83.01, E83.111, T56.0x1A) when billing the HCPCS chelation codes.

Codes always linkedHome infusion and drug administration HCPCS codes (S9355 and the J-codes/J3520) are not payable for investigational indications unless paired with qualifying ICD-10 codes and documented medical necessity.

Provider Requirements and Authorization Rules

Prior Authorization

Authorization Requirements and Prior Authorization

Prior authorization (precertification) requirements vary by site of service and product. For inpatient services described in this policy, precertification/preauthorization is required for all products when the procedure is performed inpatient. For outpatient services, prior authorization is not required for Commercial Managed Care (HMO and POS), PPO, and Indemnity products.

Inpatient: precertification/preauthorization IS REQUIRED for all products when performed inpatient.
Outpatient: Commercial Managed Care (HMO and POS), PPO, and Indemnity = Prior authorization is not required.

Denial Risk

Denial Risk for Missing Authorization

Failure to obtain required precertification/preauthorization for inpatient services may result in denial of the claim or lack of coverage. Providers should verify authorization requirements before scheduling inpatient procedures.

Background and Scope

Chelation therapy uses agents that bind metal ions to promote their excretion and is an established treatment for heavy metal toxicity (for example, lead poisoning), chronic iron overload from transfusions (transfusional hemosiderosis), and Wilson’s disease. Specific chelating agents are matched to particular toxicities (for example, calcium-EDTA for lead, deferoxamine for iron). These established uses differ from investigational or off-label applications evaluated in this policy.

Definitions and Terms

Chelation therapy (definition)

DefinitionChelation therapy: intravenous or oral administration of chelating agents that remove metal ions (eg, lead, aluminum, mercury, arsenic, zinc, iron, copper, calcium) by forming excretable complexes, used to treat metal toxicities and transfusional iron overload.

Examples of agentsSpecific agents include deferoxamine for iron toxicity and calcium-EDTA for lead poisoning; disodium EDTA is not recommended for acute lead poisoning due to hypocalcemia risk.

PurposeConverts metal toxins to forms that can be excreted in urine to reduce systemic metal burden.

MPACs (Metal protein attenuating compounds)

DefinitionMetal protein attenuating compounds (MPACs) are a class of investigational agents that modulate metal interactions and have subtle effects on metal homeostasis, studied for Alzheimer disease but not FDA‑approved for this indication.

Policy Revision History

2026-04annual_reviewLatest

Annual policy review updated summary and references; policy statement changed to add Parkinson disease to the listed investigational indications based on growing dedicated data; intent unchanged.

2024-04annual_review

Annual policy review updated references; policy statements unchanged; evidence section updated to reflect TACT2 2024 results showing failure to replicate original TACT findings for diabetic patients.

2023-04annual_review

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyChelation Therapy — Medical Necessity and Investigational Uses

Policy CodePolicy 122

Change TypeClinical updateinvestigational list expanded

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for inpatient chelation therapy; outpatient prior authorization is not required for Commercial HMO/POS, PPO, and Indemnity.

SourceLink

On This Page

Documentation Required

Coding, Documentation, and Supporting Evidence

Providers must report services using current procedure (CPT/HCPCS), revenue, and diagnosis (ICD-10) codes and include supporting documentation that justifies medical necessity. Documentation should support the diagnosis, the rationale for chelation therapy, and any trial of other modalities when required by the policy.

Report all services with the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.
Submit HCPCS codes such as J0470, J0600, J0895, J3520, S9355 when applicable and the related ICD-10 diagnosis codes (e.g., E83.01, E83.111, D56.x) that meet medical necessity criteria.
Documentation must support the diagnosis, medical necessity criteria, and rationale; lack of adequate documentation may lead to denial or classification as investigational for off-label indications.

Denial Risk

Denial Risk for Investigational/Unproven Indications

Use of chelation therapy for investigational or unproven indications listed in the policy (e.g., Alzheimer disease, arthritis, atherosclerosis, autism, diabetes, multiple sclerosis, Parkinson disease) may be denied when the evidence is insufficient to demonstrate an improvement in net health outcome.

Claims for off-label or investigational indications may be denied.
The Trial to Assess Chelation Therapy (TACT) and subsequent studies had limitations and inconsistent findings; coverage decisions rely on the policy's investigational/medically necessary distinctions.

EDTA chelation (definition)

DefinitionEDTA chelation refers to edetate disodium- or calcium-based chelation regimens (eg, calcium-EDTA used for lead poisoning; disodium EDTA noted as not recommended for acute lead poisoning due to increased hypocalcemia risk).

Clinical noteEDTA regimens have been evaluated in cardiovascular trials (eg, TACT) but findings are limited and not definitive.

Agent distinctionCalcium-EDTA is used for lead toxicity; disodium EDTA (NaEDTA) is specifically identified in the policy as not medically necessary for chelation.

Iron chelators (definition)

DefinitionIron chelators (eg, deferiprone, deferoxamine) are agents that bind excess iron to promote its excretion and have been studied for conditions including transfusional hemosiderosis and, investigationally, Parkinson disease.

Examples and evidenceDeferiprone and other iron chelators have been evaluated in Parkinson disease (eg, trials cited in the references), but evidence is currently insufficient to establish net health outcome benefit for these indications.

Use caseDeferoxamine is established for iron toxicity; deferiprone has been the subject of clinical trials in neurodegenerative conditions such as Parkinson disease.